EpiPen Recall

We have alerted members earlier this month through socal media and Be Alert of this recall but here is another reminder to check your EpiPens and encourage families to do the same.

Alphapharm Pty Ltd, following consultation with the Therapeutic Goods Administration (TGA) is recalling 4 batches of EpiPen® 300 microgram adrenaline (epinephrine) autoinjectors, used for the treatment of allergic emergencies (anaphylaxis). This recall is due to the potential that these devices may contain a defective part that may result in the device failing to activate or requiring increased force to activate.

If the EpiPen fails to activate it may result in life threatening adverse events, as the underlying anaphylaxis will not be treated. The batch numbers affected (which all expire in April 2017 are as follows: 5FA665, 5FA6651, 5FA6652, 5FA6653.

Further information is available on the ASCIA and TGA websites:

www.allergy.org.au/about-ascia/info-updates/687-urgent-tga-medicine-recall-epipen-300-batches

www.tga.gov.au/alert/epipen-300-microgram-adrenaline-injection-syringe-auto-injector

If a patient has an EpiPen® 300μg with the following batch numbers 5FA665, 5FA6651, 5FA6652 or 5FA6653 and an expiry of Apr 17, they will need to replace it with a new one as soon as possible by returning it to their pharmacist, who will replace it with an EpiPen® 300μg from a different batch FREE OF CHARGE. Patients must keep their current EpiPen® until they get a replacement and use it if required.

If an EpiPen® 300μg is not from a batch listed above or is a green EpiPen® Jr 150μg adrenaline autoinjector, the product is not affected by this recall and no action is required.